anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Background: Micro RNAs are new diagnostic markers and therapeutic targets in breast cancer research. miR-107 and miR-126 have been reported to be linked with the pathogenesis of breast cancer. The present study investigates the levels of expression of miR-107 and miR-126 in patients with breast cancer to find their correlation with the risk of breast cancer in Amritsar, Punjab, Northwest India. Material and Methods: In total, 200 subjects, 100 patients with breast cancer and 100 controls, were enrolled to screen the expression of miR-107 and miR-126 using quantitative reverse transcription polymerase chain reaction (RT-PCR) technique. The Livak method (2-ΔΔCt) was used to calculate the fold change of the expression of micro RNAs. Student t-test was used to calculate the significant change in the expression of miRNAs in patients as compared with controls. Spearman rank correlation coefficient and ROC were conducted. The value of p < 0.05 was considered to indicate a statistically significant difference. Results: miR-107 was downregulated in patients with breast cancer as compared with controls (fold change = 0.467; p = 0.114) but not statistically significant. The expression of miR-126 was found to be 5.37 times elevated in patients with breast cancer, specifically in stage I and stage III patients (p = 0.009), compared with controls, which may indicate its oncogenic activity. The ROC analyses revealed that miR-126 could be a potential diagnostic marker. In conclusion oncogenic behavior of miR-126 is suggestive of its role in pathogenesis in patients with breast cancer.
Antipsychotic intake may induce weight gain in drug-naive individuals with schizophrenia, leading to poor compliance in clinical management. However, there is still a lack of effective approaches to treat or prevent this side-effect. Therefore, we conducted this pilot study to investigate the effect of continuous theta burst stimulation (cTBS), a non-invasive magnetic stimulation technique, on preventing olanzapine-induced weight gain. Thirty-nine first-episode drug-naive individuals with schizophrenia were randomly assigned to receive either the active or sham cTBS intervention for 25 sessions (5 times per day for 5 consecutive days). The primary outcomes were changes in body weight and body mass index (BMI). Secondary outcomes included psychiatric symptoms, eating behavior scales, behavior tasks, and metabolic measures. For the result, the body weight and BMI increased significantly in the sham group but not in the active group, with a significant group effect. The active group exhibited a selective increase in the cognitive restraint domain in the Three-Factor Eating Questionnaire (TFEQ-CR) and a decrease in stop-signal reaction time compared to the sham group. The effect of cTBS on body weight was mediated by TFEQ-CR. Our findings demonstrated the feasibility that cTBS intervention could be a potential method for preventing olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients through enhancing cognitive restraint to food. Trial registration: clinical trial registered with clinicaltrials.gov (NCT05086133).
This is a multi-centre, open-label, single-dose safety, tolerability and PK-pharmacodynamics (PD) study of the vasodilator regadenoson in 3 paediatric age groups for whom a pharmacologic stress perfusion CMR test is clinically indicated; adolescents aged 12 to \<18 years (Cohort A), children aged 2 to \<12 years (Cohort B), and infants aged 1 to \<24 months and who weigh at least 3 kg (Cohort C). Regadenoson will be used as the pharmacologic stress agent in this study with MPI serving as both surrogate pharmacodynamic marker of the agent (MPR, MBF) and a clinically evaluable examination for the patient.

At least 54 paediatric patients will be enrolled at approximately 10 centres in Europe: at least 24 adolescents aged 12 to \<18 years (Cohort A), at least 18 children aged 2 to \<12 years (Cohort B), and at least 12 infants aged 1 to \<24 months (Cohort C). The study will be conducted in facilities appropriate for children, and by personnel knowledgeable and skilled in working with paediatric patients. Every attempt will be made to minimise the discomfort of the procedures to the patients. General anaesthesia/sedation with no oral-intake instructions may be used in accordance with age / disease specific requirements of the patient and as deemed necessary by the investigator per standard of care / local practice. In addition, adequate resuscitation equipment and personnel trained and certified in advanced life support must be readily available when regadenoson is administered. A Data Safety Monitoring Board (DSMB) will be in place, and will formally review all safety, efficacy, PK and PD information during the conduct of the study to ensure the safety of patients.

The study will be performed in a sequential manner across the 3 age groups, by decreasing age from adolescents (Cohort A) to children (Cohort B) and to infants (Cohort C). Dosing recommendations for the paediatric population are based on effective dose levels and PK data in adults. Based on a fixed dose of 400 µg regadenoson administered to adults with a mean body weight of 83.8 kg (body weight range: 42 to 161 kg), the effective mean weight-based dose was 4.8 µg/kg (range: 2.5 to 9.5 µg/kg). Within each age group, dosing will be extrapolated from PK-PD data obtained in adults and will be based on body weight-categories to provide approximately the same exposure as 400 µg in adults. The study will start with Cohort A (adolescents). Before the start of dosing in Cohort B, all safety, PK, and PD data obtained in Cohort A will be reviewed by the DSMB. Before the start of dosing in Cohort C, all safety, PK, and PD data obtained in Cohorts A and B will be reviewed by the DSMB.
PROBLEM TO BE SOLVED: To provide a leukocyte-removing filter medium high in leukocyte removability per unit volume and good in the flowability of a leukocyte- containing fluid, and to provide a method for using the same. SOLUTION: This leukocyte-removing filter medium comprises ultrafine fibers and short fibers having a specific average fiber diameter and an average fiber length. Therein, the ultrafine fibers are carried on the short fibers, and a network structure is formed with the ultrafine fibers. The short fibers have an average fiber diameter of 1.5-30 μm and an average fiber length of 0.5-10 mm, and the ultrafine fibers have an average fiber diameter of 0.01-1.0 μm. The porosity of the fiber medium is 50-95%, and the ultrafine fiber-holding degree of the filter medium is 0.1-30 wt.%. The ratio of the average fiber diameter of the short fibers to the average fiber diameter of the ultrafine fibers is 2-500. The method for removing leukocyte comprises filtering a leukocyte- containing fluid with the filter medium.  The leukocyte-containing fluid includes whole blood preparations, erythrocyte preparations and thrombocyte preparations.
After the surgical procedure, patients in Group S were placed in a semi-sitting position. Following skin antisepsis with 5% povidone-iodine, a sterile drape was applied. A circumferential scalp block with 2 cc of 0.25% bupivacaine was done on each of the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater occipital, and lesser occipital nerves that supply the forehead and scalp with sensory information. The procedure was performed bilaterally. The supratrochlear and supraorbital nerves were blocked at the brow, close to the upper middle edge orbit, and over the supraorbital notch that could be felt. The zygomaticotemporal nerve was blocked between the posterior edge of the zygomatic arch. The auriculotemporal nerve was blocked at the level of the tragus. The greater and lesser occipital nerves were blocked at the medial and lateral thirds of the superior nuchal line.
The invention belongs to the technical field of nano selenium, and discloses antibacterial high-dispersity nano selenium particles and a preparation method thereof. The preparation method of the invention uses selenium ion aqueous solution as selenium source and uses modified cationic amino compound as reducer. The reaction is carried out at the temperature of 30-90 ℃ and the solution turns into brick red. And centrifugally separating and drying the reactant to obtain the nano selenium particles. The preparation method is simple, the reducing group in the modified cationic amino compound is used for reducing the nano selenium, and the nano selenium is used as polysaccharide, so that the nano selenium particles are stabilized. The monodisperse spherical selenium particles prepared by the method are very stable in solution and can be kept free from agglomeration. And the prepared nano selenium particles are easy to regulate and control by changing reaction conditions.
The invention discloses compounds with antineoplastic activities. The compounds are represented by a structural formula as the following. In the formula, R represents one or two substituents of ethynyl, chlorine, fluorine, trifluoromethyl or fluorobenzoyl; X represents O or NH; Y represents CH2 or CO (carbonyl); Z represents H or methoxy; and n equals 5 or 6. According to the salicylamide compounds represented by the formula, 5-nitrosalicylic acid, 4-methoxysalicylic acid and an aniline derivative are adopted as raw materials; the raw materials are processes through steps such as amidation, reduction, and are subject to a reaction with monoethyl pimelate acyl chloride, such that a finished product is obtained. The structures of the compounds are novel, and the synthesizing method is easy to realize. As results of antineoplastic activity tests, the compounds bring inhibition effects against growths of human hepatoma carcinoma cell (HepG-2), human colonic cancer (SW 480) and human prostate carcinoma cell (PC3); and activities of most of the compounds are stronger than that of gefitinib. Therefore, the compounds can be applied in preparations of antineoplastic medicines.
Patients receiving cryo-analgesia and intercostal blocks, the patient will receive cryo-ablation prior to the intercostal block. The cryo-ablation will occur 2 cm from the sympathetic chain 2 intercostal spaces above and 2 intercostal spaces below the access incision. The patient will also receive a total of 1.0 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.
Patients started on Haemodialysis will have Cardiac MRI 3 - With Gadolinium Contrast after 6 months of therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
NEW MATERIAL:A dimethylaniline derivative of formula I. USE:Useful as a cell differentiation-inducing examination reagent or carcinogenetic agent. Since the production exhibits a strong cellular differentiation-inducing activity and has low cellular toxicity, the compound can be utilized for the clarification of cell differentiation mechanism and carcinogenesis mechanism as a biochemical reagent. Orally or parenterally administrable. PREPARATION:p-Dimethylaminobenzaldehyde of formula II is reacted with sodium cyanide and acetic acid in a solvent such as methanol at -5 deg.C to 5 deg.C to prepare a cyanhydrin ethoxyethyl ether of formula III. The compound of formula III is subsequently reacted with p-bromo-p-toluic acid methyl ester of formula IV to prepare a methyl ester of formula V. The compound of formula V is reacted with hydroxylamine in the presence of a base such as sodium hydroxide in a solvent such as methanol at the room temperature to provide the compound of formula I.
AIM: Bariatric surgery is an effective tool for weight loss and for improving weight related co-morbidities. Changes in medication usage after a silastic ring laparoscopic Roux-en-Y gastric bypass (SR-LRYGB) compared with laparoscopic sleeve gastrectomy (LSG) are unknown.
METHODS: This was a single-centre, double-blind, randomised controlled trial. Patients were randomised to either SR-LRYGB or LSG. A medication history was obtained at regular follow-up intervals, and mean numbers of prescribed medications were analysed over 5 years. Poisson regression and generalised estimating equations were used to test for statistically significant changes in usage.
RESULTS: After eight patients were lost to follow-up, data from 52 patients in each group were available for analysis. There was no difference between the SR-LRYGB or LSG groups in the number of medications prescribed, with the exception of oral glucose-lowering medications, where there was a greater decrease after SR-LRYGB compared to LSG (79% vs 55% respectively) from baseline to 5 years. At 5 years, total medication prescribed was down 10% from pre-operative levels. Prescribed insulin decreased by 72%, and cardiovascular medication decreased by 56% compared to baseline. Prescriptions for analgesia increased by 50%, psychiatric medications by 133% and proton-pump inhibitors by 81%.
CONCLUSION: Both SR-LRYGB and LSG reduced requirement for diabetic and cardiovascular medications, but increased requirement for nutritional supplementation, analgesia and psychiatric medications. There was a greater reduction in oral anti-diabetic medication prescriptions following SR-LRYGB compared to LSG, but no other difference in medication usage between surgical groups was found.
PURPOSE:To produce the liposome having stability in vivo with good reproducibility by mixing an aqueous solution contg. a substance which is contained within the space of a membrane to the acyl glycerol solution of a substance to be contained in a membrane component substance and a membrane structural substance. CONSTITUTION:The substance to be contained in the membrane component substance and the membrane structural substance is dissolved to a small amount of acylglycerol and/or a higher fatty acid to form the acylglycerol solution. Said acylglycerol solution is mixed to a small amount of the aqueous solution which contains the substance to be contained within the space surrounded by the membrance of a microspore and has pH of 4-10 followed by emulsifying the obtd. solution at a temp. of 15-65 deg.C and in the atmosphere of nitrogen gas. The stable obtd. emulsion is added to a large volume of the prescribed aqueous solution so as to maintain pH of the aqueous solution to 4-10, while agitating it to produce liposome.
The rising epidemic of obesity in the United States is accompanied by widespread public use of low carbohydrate diets for weight loss. The popularity of these diets is due partly to the promise of a "metabolic advantage" that promotes faster weight loss without an overriding sense of hunger. If this claim is true, we hypothesize that a low-carbohydrate diet will impact hormones and other factors that regulate appetite and energy balance, and result in lower energy intake and greater weight loss, than a high complex carbohydrate diet. To test this hypothesis, we will conduct a randomized, controlled feeding trial in which obese adults will be randomly assigned to one of three interventions: a low-carbohydrate-ad libitum diet, a high-carbohydrate-ad libitum diet, or a high-carbohydrate-energy-restricted diet. The low-carbohydrate diet will be modeled after the Induction Phase of the Atkins Diet. The high carbohydrate diet will be based on the "Dietary Approaches to Stop Hypertension (DASH)" diet. Participants will eat a standardized weight maintenance diet for 3 weeks. Then, for 6-weeks, participants assigned to either ad libitum group will be given their assigned diet at 120% of there estimated energy needs to maintain weight and allowed to eat as much as desired. Participants assigned to the energy-restricted group will be provided a DASH diet at 67% of their estimated energy needs to maintain weight and asked to eat all foods provided. Food intake will be measured daily. Body weight and hunger and satiety scores will be measured three times a week. Body composition and energy expenditure will be measured before and after the intervention. 24-hour profiles of hormones and other factors that influence central appetite and weight regulation (insulin, leptin, ghrelin, PYY, GLP-1) will be measured before, and on first and last days of the intervention, to compare acute and chronic metabolic effects of the diets. The analysis of primary outcomes will be based on repeated measures and longitudinal models methodology. This study offers a unique opportunity to explore how extreme differences in dietary composition, before and after weight loss, affect components of energy balance and markers of central appetite and weight regulation. These results will be used to design hypothesis-driven studies of the identified mediators of appetite and weight regulation in response to dietary manipulation.
<P>PROBLEM TO BE SOLVED: To provide an adjuvant composition suitable for use in vaccines.  <P>SOLUTION: Especially, the adjuvant composition of the invention contains saponin and an immunostimulatoty oligonucleotide, optionally with a carrier. The invention also provides vaccines containing the adjuvants of the invention and an antigen. Furthermore, a method for producing the adjuvants and the vaccines of the invention and their use as pharmaceuticals are provided. A method for treating an individual susceptible to or suffering from diseases including administration of the vaccines of the invention is also provided.  <P>COPYRIGHT: (C)2008,JPO&INPIT
PROBLEM TO BE SOLVED: To obtain a polymer of a dibenzoylmethane-based derivative which effectively absorbs ultraviolet light in an UV-A range, has high compatibility and dispersibility and excellent discoloration preventing function, and a copolymer of the dibenzoylmethane-based derivative and a polymerizable monomer, to provide a method for producing the polymer and a method for producing the copolymer, and to obtain an ultraviolet light absorber, a cosmetic and a resin composition comprising the polymer or the copolymer and a molding composed of the resin composition. SOLUTION: This polymer of the dibenzoylmethane-based derivative represented by general formula (I) is obtained. This copolymer comprises the dibenzoylmethane-based derivative and the polymerizable monomer. This polymer composition comprises the polymer or the copolymer and another polymer. This method for producing the polymer is provided and a method for producing the copolymer is provided. Uses of the polymer and the copolymer are provided.
All the patients in each group of laryngeal mask airway will contain 20 patients. In all groups middle ear pressures will be measured, in both right and left ear, preoperatively, after induction of anesthesia, insertion of laryngeal mask and in 1st., 5th., 10th. minutes and every 5 minutes perioperatively and recorded. Also the heart rates,arterial oxygen saturation (SaO2), airway pressures and end-tidal carbon dioxide values will be recorded before and following induction of anesthesia and in 1st., 5th., 10th. minutes and every five minutes perioperatively. Patients will be followed during the hospital stay for any complications.In all groups premedication will be done with midazolam. Anesthesia will be inducted with propofol and fentanyl; and maintained with sevoflurane-air combination.
The present invention provides devices and methods for treating biological tissue. The treatment comprise implanting a scaffold implant device into in combination with a therapeutic material such as cells, tissue or cell components. The scaffold device serves to hold the therapeutic material at the treatment site, protecting it from being squeezed out by surrounding tissue. Additionally the scaffold device is believed to trigger an injury response that leads to angiogenesis in the tissue, which provides blood flow and nutrients to the associated therapeutic material to sustain it for a therapeutically effective amount of time. The devices may also be implanted at a tissue site already treated with a therapeutic material to initiate angiogenesis at the treatment site to sustain the material. The devices and methods also may be used to treat tumors with a necrosis factor.
Patients in this group are to receive a single dose of TACE treatment on day 1, followed by arsenic trioxide at 10 mg/day for 14 days (day 8-21). TACE treatment is repeated every 9 weeks while arsenic trioxide every 3 weeks for treatment duration of 27 weeks. At least 3 cycles of arsenic trioxide are administrated.
### Teratogenic Effects

Flucytosine was shown to be teratogenic (vertebral fusions) in the rat at doses of 40 mg/kg/day (298 mg/M2/day or 0.051 times the human dose) administered on days 7 to 13 of gestation. At higher doses (700 mg/kg/day; 5208 mg/M2/day or 0.89 times the human dose administered on days 9 to 12 of gestation), cleft lip and palate and micrognathia were reported. Flucytosine was not teratogenic in rabbits up to a dose of 100 mg/kg/day (1423 mg/M2/day or 0.243 times the human dose) administered on days 6 to 18 of gestation. In mice, 400 mg/kg/day of flucytosine (1380 mg/M2/day or 0.236 times the human dose) administered on days 7 to 13 of gestation was associated with a low incidence of cleft palate that was not statistically significant. Studies in pregnant rats have shown that flucytosine injected intraperitoneally crosses the placental barrier. There are no adequate and well-controlled studies in pregnant women. Flucytosine Capsules should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
GCA is a rare autoimmune disorder and is the most common type of inflammation of medium- to large-sized blood vessels in the body. It usually only occurs in older adults. The most common symptoms of GCA include headache, pain in the shoulders and hips (polymyalgia rheumatica), pain in the jaw (jaw claudication), fever, and blurred vision. Organ-specific markers of injury or damage as well as direct markers of vascular damage and inflammation are currently used by clinicians to assess GCA disease progression; however, these markers are not very useful in guiding treatment. There are also blood tests that clinicians use to monitor GCA activity, such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), but these tests lack specificity and sensitivity. Most treatments available now for GCA are toxic, therefore if other markers indicating disease activity can be found, it may lead to the development of less toxic treatments. This study will use new scientific methods to identify new biomarkers that can be used to monitor disease activity in GCA patients. These biomarkers may be used to help direct clinical care for GCA patients and assist in future drug development.

Study visits will occur monthly for the first year, then every 3 months thereafter for the remainder of the study. Blood and urine collection will occur at every visit. A physical exam and medical and medication history will occur every 3 months; also, participants will be asked to complete several questionnaires to assess disease activity, health status, and tobacco, alcohol, and drug use. Participants may have additional study visits if a disease flare or disease-related complications occur during the study.